CN Patent

CN105764570B — 用于克服化学治疗抗性的雷公藤内酯甲

Assigned to Western University of Health Sciences · Expires 2020-01-17 · 6y expired

What this patent protects

本发明提供了用于克服癌症治疗中(特别是对化学治疗药物的治疗已表现出抗性的癌症治疗中)之抗药性的包含雷公藤内酯甲的组合物。公开了用于治疗癌症的方法和组合物。所述方法向有此需要的患者施用雷公藤内酯甲和化学治疗药物的组合。以有效治疗癌症的组合量施用雷公藤内酯甲和化学治疗药物。治疗的癌症至少部分地对通过单独化学治疗药物的治疗有抗性。

USPTO Abstract

本发明提供了用于克服癌症治疗中(特别是对化学治疗药物的治疗已表现出抗性的癌症治疗中)之抗药性的包含雷公藤内酯甲的组合物。公开了用于治疗癌症的方法和组合物。所述方法向有此需要的患者施用雷公藤内酯甲和化学治疗药物的组合。以有效治疗癌症的组合量施用雷公藤内酯甲和化学治疗药物。治疗的癌症至少部分地对通过单独化学治疗药物的治疗有抗性。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN105764570B
Jurisdiction: CN
Classification: —
Expires: 2020-01-17
Drug substance claim: No
Drug product claim: No
Assignee: Western University of Health Sciences
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.